Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Methods: This retrospective study used MRI data of acute ischemic stroke patients from the prospective observational single-center 1000Plus study, acquired between September ... Daiichi-Sankyo, EISAI, ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

This makes Eli Lilly considerably more desirable compared to Novo Nordisk, which is still in the process of optimizing its manufacturing processes following its recent acquisition of Catalent to ...

Ore Huiying / Bloomberg / Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect. Eli Lilly missed analysts’ revenue expectations by 6% last quarter ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...

Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales and profit for Eli Lilly in ...

Eli Lilly (NYSE:LLY) is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are expected ...

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...

Eli Lilly exceeded analyst forecasts for both sales and earnings in Q4 2024. As has been true for a while, sales of GLP-1 drugs Mounjaro and Zepbound drove both sales and earnings growth.